Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

JPMorgan Chase, Wells Fargo and BlackRock reported strong quarterly results to kick off earnings season, but concerns linger ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.

Shares of Pfizer Inc. PFE shed 2.82% to $29.34 Thursday, on what proved to be an all-around grim trading session for the ...

As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...